RT Journal Article
SR Electronic
T1 Characterization of highly active mutational signatures in tumors from a large Chinese population
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.11.03.23297964
DO 10.1101/2023.11.03.23297964
A1 Chevalier, Aaron
A1 Guo, Tao
A1 Gurevich, Natasha Q.
A1 Xu, Jingwen
A1 Yajima, Masanao
A1 Campbell, Joshua D.
YR 2023
UL http://medrxiv.org/content/early/2023/11/04/2023.11.03.23297964.abstract
AB The majority of mutational signatures have been characterized in tumors from Western countries and the degree to which mutational signatures are similar or different in Eastern populations has not been fully explored. We leveraged a large-scale clinical sequencing cohort of tumors from a Chinese population containing 25 tumor types and found that the highly active mutational signatures were similar to those previously characterized1,2. The aristolochic acid signature SBS22 was observed in four soft tissue sarcomas and the POLE-associated signature SBS10 was observed in a gallbladder carcinoma. In lung adenocarcinoma, the polycyclic aromatic hydrocarbon (PAH) signature SBS4 was significantly higher in males compared to females but not associated with smoking status. The UV-associated signature SBS7 was significantly lower in cutaneous melanomas from the Chinese population compared to a similar American cohort. Overall, these results add to our understanding of the mutational processes that contribute to tumors from the Chinese population.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the National Cancer Institute (NCI) Informatics Technology for Cancer Research (ITCR) 1U01CA253500 (J.D. Campbell and M. Yajima). We thank Drs. Kai Wang and Xiaoliang Shi for helpful insights about the OrigiMed dataset.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The data were openly available before publication of our study, from OrigiMed and MSK and are respectively available at the following links: https://www.cbioportal.org/study/summary?id=pan_origimed_2020 https://www.cbioportal.org/study/summary?id=msk_impact_2017I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data were openly available before publication of our study, from OrigiMed and MSK and are respectively available at the following links: https://www.cbioportal.org/study/summary?id=pan_origimed_2020 https://www.cbioportal.org/study/summary?id=msk_impact_2017https://www.cbioportal.org/study/summary?id=pan_origimed_2020https://www.cbioportal.org/study/summary?id=msk_impact_2017